dengu
virus
denv
caus
agent
dengu
fever
df
dengu
hemorrhag
fever
dhf
review
current
state
knowledg
human
antibodi
respons
dengu
identifi
import
knowledg
gap
larg
bodi
work
demonstr
antibodi
neutral
enhanc
denv
infect
investig
mainli
use
mous
monoclon
antibodi
mab
studi
interact
denv
antibodi
studi
indic
antibodi
neutral
denv
multihit
phenomenon
requir
bind
multipl
antibodi
neutral
virion
potent
neutral
mous
mab
bind
surfac
expos
epitop
domain
iii
dengu
envelop
e
protein
one
challeng
face
dengu
field
extend
studi
mous
mab
better
understand
human
antibodi
respons
human
antibodi
respons
complex
involv
polyclon
respons
primari
secondari
infect
differ
denv
serotyp
review
studi
conduct
immun
sera
mab
isol
peopl
expos
dengu
infect
denguespecif
antibodi
human
immun
sera
weakli
neutral
bind
multipl
denv
serotyp
human
antibodi
potent
type
specif
neutral
denv
repres
small
fraction
total
denvspecif
antibodi
respons
moreov
neutral
antibodi
appear
bind
novel
epitop
includ
complex
quaternari
epitop
preserv
intact
virion
studi
establish
human
mous
antibodi
recogn
distinct
epitop
dengu
virion
lead
theori
propos
explain
increas
risk
sever
diseas
secondari
case
antibodi
depend
enhanc
ade
postul
weakli
neutral
antibodi
first
infect
bind
second
serotyp
enhanc
infect
bear
myeloid
cell
monocyt
virus
macrophag
review
result
human
anim
cell
cultur
studi
relev
ade
hypothesi
understand
human
antibodi
neutral
enhanc
denv
possibl
better
evalu
exist
vaccin
develop
next
gener
novel
vaccin
dengu
virus
denv
emerg
mosquitoborn
flavivirus
caus
agent
dengu
fever
df
dengu
hemorrhag
fever
dhf
million
peopl
live
tropic
subtrop
region
world
infect
denv
year
sever
hundr
thousand
infect
progress
dhf
life
threaten
diseas
denv
complex
consist
distinct
relat
virus
design
serotyp
denv
display
antibodi
epitop
uniqu
serotyp
epitop
share
serotyp
peopl
recov
primari
denv
infect
develop
robust
antibodi
respons
cross
react
serotyp
despit
cross
reactiv
antibodi
prevent
reinfect
serotyp
homolog
serotyp
individu
suscept
second
infect
differ
serotyp
heterolog
serotyp
peopl
experienc
secondari
dengu
infect
new
serotyp
face
much
greater
risk
develop
dhf
indic
preexist
immun
denv
exacerb
diseas
antibodi
depend
enhanc
ade
denv
wide
support
theori
explain
higher
risk
dhf
associ
secondari
infect
thu
antibodi
respons
denv
infect
complex
potenti
benefit
harm
host
current
mani
dengu
vaccin
develop
includ
live
attenu
denv
vaccin
enter
phase
iii
human
trial
indepth
understand
human
antibodi
respons
denv
highli
relev
evalu
vaccin
alreadi
pipelin
develop
new
vaccin
review
current
state
knowledg
human
antibodi
respons
denv
infect
identifi
import
gap
knowledg
structur
arrang
viral
surfac
protein
play
import
role
dictat
antibodi
neutral
virus
dengu
envelop
positivestrand
rna
viru
produc
spheric
particl
diamet
approxim
viral
envelop
contain
two
integr
membran
protein
design
envelop
e
pre
membran
prm
e
protein
bind
cellular
receptor
mediat
fusion
viral
cellular
membran
viral
entri
cell
e
protein
also
main
target
neutral
antibodi
crystal
structur
e
protein
sever
flavivirus
solv
individu
subunit
e
protein
consist
three
betabarrel
domain
design
domain
edi
ii
edii
iii
ediii
nativ
protein
form
headtotail
homodim
figur
hydrophob
viral
fusion
peptid
locat
tip
domain
ii
shield
domain
iii
adjac
subunit
domain
iii
appear
respons
bind
cellular
receptor
sever
mutat
affect
receptor
bind
locat
domain
detail
pictur
e
protein
dimer
organ
surfac
matur
infecti
virion
obtain
combin
crystal
structur
e
cryoem
reconstruct
entir
virion
figur
viru
particl
monom
e
organ
tightli
pack
dimer
lie
flat
surfac
viral
membran
figur
anoth
import
featur
individu
e
subunit
organ
fold
axe
icosahedr
structur
virion
thu
e
protein
subunit
ident
environ
viral
surfac
steric
consider
result
preferenti
interact
e
subunit
other
receptor
antibodi
e
protein
matur
virion
homodim
subunit
three
domain
design
red
ii
yellow
iii
blue
b
arrang
e
protein
surfac
virion
imag
b
dengu
virion
assembl
membran
endoplasm
reticulum
er
viru
bud
lumen
er
immatur
virion
unlik
matur
virion
smooth
surfac
immatur
virion
bud
er
rough
surfac
creat
trimer
eprm
heterodim
form
spike
viral
envelop
review
figur
immatur
particl
transit
matur
particl
secret
infect
cell
transgolgi
compart
cellular
proteas
cleav
prm
protein
gener
matur
protein
also
result
rearrang
e
protein
trimer
form
dimer
lie
flat
surfac
envelop
creat
smooth
surfac
observ
matur
infecti
virion
review
figur
practic
process
intracellular
denv
matur
appear
ineffici
mani
immatur
partial
matur
virion
also
releas
infect
cell
moreov
recent
studi
indic
partial
matur
even
fulli
immatur
particl
infecti
condit
structur
matur
properti
denv
must
consid
defin
epitop
engag
human
antibodi
function
consequ
antibodi
bind
matur
dengu
virion
dengu
virion
bud
endoplasm
reticulum
immatur
noninfecti
particl
surfac
immatur
particl
jag
appear
prm
e
protein
initi
assembl
trimer
spike
protrud
away
envelop
transgolgi
compart
cellular
proteas
cleav
prm
protein
gener
matur
protein
also
result
rearrang
e
protein
trimer
form
dimer
lie
flat
surfac
envelop
creat
smooth
surfac
observ
matur
infecti
virion
releas
extracellular
space
imag
reproduc
studi
understand
antibodi
neutral
enhanc
denv
done
mous
monoclon
antibodi
mab
review
e
protein
main
antigen
expos
surfac
virion
mous
mab
bind
e
protein
focu
much
studi
although
neutral
mous
mab
map
three
domain
strongli
neutral
mab
serotypespecif
bind
domain
iii
e
protein
ediii
protrud
surfac
virion
figur
two
partial
overlap
epitop
ediii
design
later
ridg
strand
epitop
main
target
mous
mab
neutral
denv
later
ridg
epitop
interact
serotypespecif
strongli
neutral
antibodi
mous
mab
bind
strand
epitop
cross
react
one
serotyp
denv
design
dengu
sub
complex
neutral
mab
mous
antibodi
also
use
explor
mechan
dengu
neutral
potenti
bind
site
virion
antibodi
bind
e
protein
howev
indic
molecul
unlik
bound
antibodi
steric
effect
limit
access
epitop
exampl
sever
ediii
close
pack
around
axi
fold
symmetri
figur
antibodi
bind
one
ediii
obstruct
antibodi
bind
adjac
ediii
also
becom
clear
hypothet
structur
matur
flaviviru
particl
gener
cryoem
molecular
fit
alway
predict
epitop
exposur
bind
e
reactiv
antibodi
depend
dynam
movement
protein
molecul
breath
virion
particl
lead
transient
exposur
hidden
epitop
instanc
optim
bind
mous
mab
ediii
requir
incub
structur
bound
ediii
indic
antibodi
bind
site
transient
expos
viral
breath
least
two
distinct
mechan
mous
mab
neutral
denv
cell
cultur
antibodi
neutral
block
attach
viru
cell
wherea
other
neutral
block
post
attach
step
entri
process
review
antibodi
neutral
postattach
step
presum
block
viral
fusion
cellular
membran
low
ph
trigger
flaviviru
fusion
requir
larg
conform
chang
e
protein
molecul
antibodi
may
interfer
process
requir
entri
flaviviru
neutral
requir
bind
multipl
antibodi
review
studi
ediii
bind
mab
potent
neutral
west
nile
viru
post
attach
stage
indic
antibodi
need
bind
effect
neutral
base
studi
pierson
colleagu
propos
flavivirus
neutral
number
antibodi
bound
virion
exce
critic
threshold
import
implic
threshold
model
affin
antibodi
bind
total
number
access
epitop
contribut
neutral
potenc
antibodi
thu
even
antibodi
bind
high
affin
antibodi
fail
neutral
number
access
epitop
threshold
requir
neutral
convers
lower
affin
antibodi
may
neutral
mani
epitop
access
bind
potent
neutral
antibodi
would
bind
high
affin
epitop
expos
present
larg
number
surfac
virion
unclear
result
broadli
gener
antibodi
neutral
flavivirus
word
threshold
true
flaviviru
bind
antibodi
altern
threshold
chang
depend
locat
bind
threshold
model
hold
pre
post
attach
neutral
mab
rule
depend
cell
type
infect
well
entri
receptor
fc
receptor
express
cell
final
importantli
threshold
model
appli
viru
neutral
immun
sera
multipl
antibodi
bind
differ
epitop
come
contact
virion
peopl
expos
denv
infect
detect
specif
antibodi
decad
longer
larg
fraction
respons
cross
react
serotyp
even
flavivirus
fact
domin
cross
reactiv
antibodi
preclud
use
simpl
antigen
bind
assay
identifi
flaviviru
respons
infect
function
neutral
antibodi
respons
specif
use
identifi
flaviviru
respons
infect
earli
studi
durabl
immun
respons
follow
denv
infect
conduct
sabin
sabin
infect
naiv
volunt
ngc
denv
hawaii
rechalleng
individu
homolog
viru
differ
time
first
infect
subject
protect
month
last
time
point
studi
reinfect
serotyp
howev
challeng
heterolog
serotyp
cross
protect
last
month
first
infect
heterolog
infect
produc
clinic
sign
diseas
also
produc
suffici
viremia
mosquito
acquir
infect
sabin
work
demonstr
protect
long
term
homolog
serotyp
transient
heterolog
serotyp
observ
agreement
natur
histori
studi
dengu
endem
countri
indic
primari
infect
follow
sever
month
transient
period
broad
protect
long
term
protect
respons
specif
infect
serotyp
recent
studi
chan
colleagu
provid
molecular
basi
initi
broad
cross
neutral
respons
investig
demonstr
earli
convalesc
sera
contain
high
concentr
weakli
neutral
cross
reactiv
antibodi
capabl
form
larg
virusantibodi
aggreg
bound
inhibitori
receptor
surfac
monocyt
protect
afford
class
antibodi
like
transient
level
cross
reactiv
antibodi
declin
time
contrast
potent
neutral
typespecif
antibodi
requir
format
aggreg
effect
neutral
type
specif
neutral
antibodi
detect
even
year
primari
infect
sever
month
primari
dengu
infect
individu
suscept
secondari
infect
new
serotyp
hallmark
secondari
dengu
rapid
elev
antibodi
respons
compar
primari
respons
rapid
elev
respons
caus
stimul
memori
bcell
primari
infect
first
antibodi
appear
follow
secondari
infect
neutral
serotyp
respons
primari
infect
better
second
viru
phenomenon
term
origin
antigen
sin
although
molecular
basi
mechan
respons
incomplet
understood
time
neutral
antibodi
respons
broaden
key
featur
secondari
dengu
longlast
respons
neutral
multipl
serotyp
includ
serotyp
previous
infect
individu
tertiari
denv
infect
document
rare
support
notion
secondari
infect
stimul
long
term
cross
neutral
antibodi
may
even
effect
serotyp
encount
previous
investig
also
character
kinet
isotyp
denvspecif
serum
antibodi
respons
infect
peopl
follow
primari
denv
infect
denvspecif
igm
antibodi
appear
day
onset
fever
measur
month
igg
antibodi
first
appear
week
onset
fever
igg
respons
peak
sever
week
infect
declin
lower
level
persist
decad
longer
denv
infect
mainli
induc
subclass
antibodi
indic
bias
immun
respons
wnv
infect
also
induc
strong
respons
protect
cell
cultur
anim
serum
antibodi
respons
differ
follow
primari
secondari
denv
infect
antibodi
produc
second
infect
aris
bcell
memori
bcell
gener
primari
infect
secondari
infect
stimul
bcell
memori
lead
rapid
rise
denvspecif
igg
measur
even
first
day
symptom
moreov
denvspecif
serum
igg
titer
much
higher
secondari
compar
primari
infect
reason
complet
understood
secondari
dengu
igm
respons
variabl
case
undetect
comparison
work
done
mous
mab
begin
learn
main
antigen
epitop
dengu
virion
target
human
antibodi
studi
done
dengu
immun
sera
human
mab
defin
specif
human
respons
start
describ
studi
dengu
immun
sera
move
studi
human
mab
denv
infect
peopl
develop
serum
antibodi
structur
protein
e
prm
c
well
nonstructur
protein
investig
report
higher
level
prm
antibodi
secondari
compar
primari
infect
howev
unclear
due
overal
high
level
antibodi
secondari
infect
antibodi
respons
prm
specif
elev
secondari
infect
antibodi
bind
particularli
interest
nonstructur
protein
secret
infect
cell
one
mous
model
lethal
dengu
infect
antibodi
protect
also
report
antibodi
cross
react
selfantigen
platelet
endotheli
cell
investig
propos
possibl
mechan
damag
vasculatur
sever
dengu
review
although
antibodi
detect
peopl
antibodi
unlik
influenc
infect
diseas
intracellular
antigen
would
encount
antibodi
serum
antibodi
denv
e
protein
focu
sever
studi
main
antigen
virion
surfac
target
neutral
antibodi
mutat
conserv
fusion
loop
domain
ii
e
protein
reduc
bind
immun
sera
substanti
indic
fusion
loop
region
major
target
human
antibodi
respons
howev
fusion
loop
antibodi
unlik
target
serotypespecif
potent
neutral
antibodi
fusion
loop
well
conserv
serotyp
follow
mous
mab
studi
investig
test
ediii
epitop
main
target
neutral
antibodi
human
immun
sera
well
ediii
antibodi
present
low
level
human
immun
sera
crill
cowork
observ
correl
level
ediii
antibodi
neutral
potenc
immun
serum
sampl
howev
wahala
midg
use
recombin
ediii
protein
deplet
sera
ediii
bind
antibodi
observ
small
effect
neutral
follow
remov
ediii
bind
antibodi
studi
immun
sera
hors
peopl
expos
west
nile
viru
also
demonstr
neutral
antibodi
gener
follow
natur
infect
mainli
direct
epitop
ediii
thu
main
epitop
denv
target
neutral
antibodi
immun
sera
remain
defin
sever
group
gener
panel
dengu
reactiv
human
monoclon
antibodi
hmab
hmab
gener
use
method
ebv
transform
memori
bcell
dengu
immun
subject
previous
assum
e
protein
main
target
antibodi
hmab
indic
complex
pictur
e
prm
common
target
human
antibodi
particularli
interest
class
hmab
bound
intact
virion
individu
subunit
e
prm
latter
class
indic
bcell
epitop
express
viral
protein
assembl
form
virion
studi
dengu
immun
sera
also
indic
serum
antibodi
bind
ectodomain
e
express
recombin
antigen
indic
substanti
fraction
antibodi
bind
prm
andor
e
epitop
express
virion
function
major
human
mab
produc
weakli
neutral
serotyp
cross
reactiv
consist
observ
dengu
specif
antibodi
circul
also
cross
reactiv
weakli
neutral
potent
neutral
hmab
rare
indic
small
fraction
total
antibodi
respons
respons
viru
neutral
neutral
hmab
includ
antibodi
bind
virion
recombin
e
protein
antibodi
bind
ediii
antibodi
bind
later
ridg
strand
epitop
ediii
see
figur
result
demonstr
human
neutral
antibodi
bind
well
defin
epitop
ediii
well
novel
epitop
ediii
epitop
preserv
intact
virion
nonhuman
primat
also
develop
potent
neutral
antibodi
bind
novel
epitop
chimpanze
mab
potent
neutral
typespecif
antibodi
map
edi
particular
interest
studi
conduct
diamond
colleagu
hmab
gener
peopl
recov
west
nile
viru
infect
two
strongli
neutral
hmab
bound
west
nile
virion
recombin
e
protein
structur
one
antibodi
bound
west
nile
virion
demonstr
antibodi
bound
complex
epitop
span
ediii
ediii
adjac
dimer
figur
consist
observ
class
antibodi
bound
virion
recombin
e
protein
antibodi
appear
block
infect
cross
link
e
protein
virion
block
conform
chang
requir
viral
entri
fusion
summari
result
demonstr
human
antibodi
potent
type
specif
neutral
denv
repres
small
fraction
total
denvspecif
antibodi
respons
moreov
neutral
antibodi
appear
bind
novel
epitop
includ
complex
quaternari
epitop
preserv
intact
virion
approxim
footprint
human
mab
circl
note
foot
print
encompass
ediii
ediii
adjac
dimer
one
hundr
twenti
epitop
predict
avail
virion
antibodi
bind
figur
adapt
surprisingli
high
proport
hmab
bound
prm
antigen
receiv
much
attent
antibodi
target
prm
antibodi
cross
react
serotyp
neutral
capac
rang
poor
moder
best
prm
reactiv
antibodi
enhanc
denv
infect
bear
cell
vitro
larg
rang
antibodi
concentr
indic
potenti
involv
antibodi
depend
enhanc
ade
dengu
discuss
later
review
denv
within
serotyp
genet
divers
classifi
distinct
genotyp
differ
geograph
distribut
pathogen
potenti
review
despit
genet
variabl
wide
assum
neutral
antibodi
epitop
conserv
among
strain
belong
serotyp
fact
current
strategi
develop
dengu
vaccin
base
assumpt
neutral
immun
respons
direct
singl
strain
protect
strain
denv
within
serotyp
idea
strain
variat
within
serotyp
affect
neutral
mainli
base
observ
human
cohort
studi
one
rare
ever
observ
reinfect
serotyp
argu
observ
alon
mean
intraserotyp
strain
variat
irrelev
neutral
cohort
studi
done
area
serotyp
repres
circul
singl
genotyp
need
prospect
studi
specif
assess
happen
new
genotyp
introduc
popul
preexist
immun
serotyp
sever
recent
laboratori
base
studi
indic
intraserotyp
variat
lead
larg
differ
antibodi
neutral
blaney
colleagu
immun
monkey
candid
live
attenu
dengu
vaccin
character
immun
respons
monkey
use
panel
virus
repres
serotyp
genotyp
within
serotyp
observ
larg
differ
neutral
titer
compar
differ
genotyp
studi
pediatr
dengu
case
thailand
investig
observ
signific
differ
abil
sera
neutral
refer
clinic
strain
guzman
colleagu
report
amino
acid
sequenc
differ
strain
strong
influenc
viru
neutral
murin
human
immun
sera
studi
flavivirus
also
demonstr
neutral
depend
lineag
strain
use
assay
seri
studi
group
diamond
group
recent
demonstr
abil
mani
monoclon
antibodi
neutral
depend
genotyp
use
neutral
test
studi
also
led
identif
point
mutat
profoundli
alter
neutral
titer
recent
observ
fold
differ
neutral
titer
human
immun
sera
recombin
virus
prm
e
differ
genotyp
use
neutral
test
thu
current
paradigm
neutral
antibodi
epitop
conserv
within
serotyp
need
test
vigor
field
laboratori
studi
need
assess
relationship
cell
cultur
antibodi
neutral
denv
vivo
protect
infect
diseas
typic
cell
cultur
neutral
base
antibodi
bind
virion
directli
interf
infect
vivo
situat
complex
antibodi
interact
compon
immun
system
complement
fc
receptor
augment
suppress
viru
neutral
moreov
antibodi
also
har
cellular
mechan
phagocytosi
antibodi
depend
cellular
cytotox
adcc
control
denv
infect
despit
differ
studi
report
strong
correl
vitro
neutral
potenc
vivo
protect
monoclon
antibodi
polyclon
sera
recent
studi
infant
matern
deriv
denvspecif
antibodi
indic
invitro
neutral
titer
predict
protect
vivo
well
howev
flaviviru
antibodi
poor
natur
activ
cell
cultur
protect
diseas
anim
model
studi
need
defin
main
mechan
antibodi
protect
peopl
sever
dengu
diseas
detail
work
date
human
antibodi
respons
denv
focus
circul
serum
antibodi
mab
gener
memori
bcell
pool
studi
need
identifi
actual
bcell
subset
activ
dengu
character
function
import
antibodi
produc
differ
bcell
popul
antibodi
stimul
virus
classic
tdepend
respons
deriv
follicular
bcell
main
antibodi
respons
denv
also
like
involv
tdepend
follicular
bcell
differenti
long
live
plasma
cell
memori
bcell
recent
studi
indic
less
well
studi
bcell
subset
margin
zone
bcell
cell
give
rise
natur
tindepend
antibodi
respons
provid
protect
virus
studi
need
assess
similar
respons
constitut
import
compon
respons
denv
well
regard
recent
observ
mani
human
flaviviru
antibodi
recogn
epitop
preserv
intact
virion
recombin
e
protein
intrigu
antibodi
may
produc
multival
viru
particl
directli
activ
bcell
without
tcell
help
denv
infect
also
inhibit
type
interferon
respons
suppress
antigen
present
myeloid
cell
effect
like
influenc
qualiti
adapt
immun
respons
includ
antibodi
product
need
invest
human
studi
anim
model
character
bcell
subset
involv
respons
denv
particular
attent
respons
differ
primari
versu
secondari
case
sever
versu
mild
diseas
case
mani
studi
differ
region
world
document
individu
expos
secondari
infect
greater
risk
develop
sever
diseas
compar
individu
expos
primari
infect
review
lead
theori
propos
explain
increas
risk
sever
diseas
secondari
case
antibodi
depend
enhanc
ade
postul
weakli
neutral
antibodi
first
infect
bind
second
serotyp
enhanc
infect
bear
myeloid
cell
monocyt
macrophag
review
discuss
evid
ade
human
anim
cell
cultur
studi
fact
secondari
infect
lead
higher
serum
viremia
greater
risk
sever
diseas
compar
primari
infect
strongli
suggest
preexist
immun
necessarili
antibodi
denv
risk
factor
sever
dengu
compel
evid
ade
come
studi
infant
passiv
acquir
antibodi
denv
mother
soon
birth
high
level
matern
antibodi
appear
protect
infant
dengu
infant
born
dengu
immun
mother
greatest
risk
develop
sever
dengu
month
birth
attribut
matern
antibodi
decay
low
subneutr
level
enhanc
denv
studi
older
children
experienc
secondari
infect
also
provid
evid
support
ade
sever
diseas
one
studi
abil
immun
sera
collect
second
infect
enhanc
denv
cell
cultur
posit
correl
risk
sever
diseas
howev
human
studi
support
ade
theori
dhfdss
instanc
studi
matern
transfer
antibodi
infant
librati
et
al
find
signific
associ
ade
diseas
outcom
prospect
studi
school
children
thailand
ade
activ
preill
undilut
sera
correl
sever
diseas
sever
viral
load
follow
secondari
infect
difficult
directli
compar
differ
studi
differ
studi
design
method
ade
hypothesi
biolog
plausibl
support
suffici
evid
justifi
conduct
human
cohort
studi
specif
design
test
ade
hypothesi
proven
challeng
test
ade
hypothesi
anim
model
denv
replic
poorli
anim
dhf
dss
difficult
reproduc
anim
model
nonetheless
studi
indic
antibodi
enhanc
infect
sever
diseas
reproduc
anim
studi
nonhuman
primat
demonstr
anim
treat
subneutr
level
antibodi
develop
higher
serum
viremia
compar
untreat
anim
howev
attempt
reproduc
dhf
nonhuman
primat
unsuccess
investig
attempt
success
develop
mous
model
denv
infect
diseas
review
success
mous
model
antibodi
enhanc
sever
diseas
base
infect
interferon
receptordefici
mice
mous
adapt
strain
mice
treat
antidengu
monoclon
antibodi
polyclon
sera
infect
denv
develop
lethal
vascular
leak
diseas
similar
dhf
cell
involv
ade
driven
infect
fc
receptor
bear
cell
includ
sinusoid
endotheli
cell
liver
addit
vascular
leakag
diseas
character
elev
level
cytokin
thrombocytopenia
similar
sever
denv
ill
human
specif
cellular
mechan
lead
vascular
leakag
like
differ
human
mice
especi
mice
defici
interferon
receptor
anim
studi
establish
antibodi
enhanc
viral
replic
induc
host
cytokin
respons
lead
clinic
outcom
similar
dhfdss
develop
appropri
anim
model
includ
mice
reconstitut
human
immun
cell
ongo
excit
area
dengu
research
ade
phenomenon
reproduc
cell
cultur
model
receptor
bear
human
cell
line
monocyt
macrophag
effici
infect
denv
alon
becom
highli
permiss
infect
presenc
subneutr
antibodi
concentr
ade
well
demonstr
monoclon
antibodi
polyclon
sera
vitro
use
receptor
bear
human
cell
primari
human
monocyt
macrophag
dendrit
cell
initi
believ
ade
simpli
result
greater
number
infect
cell
produc
infecti
virion
extrins
ade
howev
recent
studi
ubol
colleagu
cell
human
acut
monocyt
leukemia
cell
line
indic
phenomenon
complex
denv
enter
cell
via
fc
receptor
suppress
type
interferon
respons
activ
cellular
antivir
molecul
effect
denv
infect
cell
absenc
antibodi
moreov
cell
infect
presenc
antibodi
produc
infecti
viru
per
infect
cell
compar
cell
infect
absenc
antibodi
phenomenon
term
intrins
ade
demonstr
antibodi
mediat
infect
lead
suppress
antivir
state
within
infect
cell
releas
greater
quantiti
infecti
virion
infect
cell
compar
cell
infect
antibodyindepend
entri
ubol
observ
intrins
ade
confirm
group
work
primari
human
cell
although
specif
mechan
molecul
implic
appear
depend
cell
type
use
variabl
introduc
differ
laboratori
perform
studi
cell
antibodi
depend
infect
inhibit
type
interferon
respons
increas
level
suppress
cytokin
studi
primari
human
pbmc
one
group
observ
differ
type
type
ifn
level
wherea
anoth
group
observ
decreas
level
type
interferon
increas
level
boonak
colleagu
compar
ade
infect
monocyt
macrophag
dendrit
cell
observ
increas
product
primari
monocyt
macrophag
dendrit
cell
pictur
emerg
studi
antibodycomplex
dengu
virus
infect
cell
via
receptor
lead
suppress
cellular
antivir
respons
studi
need
better
defin
cellular
pathway
mechan
contribut
phenotyp
well
establish
almost
dengu
specif
mab
use
subneutr
concentr
enhanc
infect
cultur
cell
express
appropri
receptor
studi
need
identifi
specif
antibodi
subpopul
dengu
immun
human
sera
drive
ade
cell
cultur
anim
model
potenti
peopl
expos
secondari
infect
design
studi
import
keep
mind
secondari
denv
infect
ade
like
occur
circul
antibodi
concentr
present
acut
phase
infect
recent
studi
demonstr
quantit
differ
abil
primari
immun
sera
enhanc
homolog
versu
heterolog
denv
serotyp
sera
dilut
artifici
low
concentr
enhanc
homolog
viru
wherea
heterolog
serotyp
enhanc
high
serum
concentr
like
encount
viru
respons
secondari
infect
actual
target
antibodi
human
immun
sera
enhanc
denv
infect
identifi
regard
previous
mention
predomin
prm
hmab
rais
intrigu
possibl
antibodi
play
pivot
role
enhanc
human
denv
infect
denv
produc
cell
cultur
complex
mix
immatur
partial
matur
fulli
matur
virion
prepar
effici
enhanc
vitro
mice
prm
antibodi
identifi
main
antibodi
immun
sera
potenti
enhanc
dengu
physiolog
concentr
possibl
design
vaccin
neutral
without
potenti
enhanc
although
much
remain
learn
denv
pathogenesi
antibodi
emerg
import
host
molecul
reduc
exacerb
diseas
sever
mous
mab
taught
us
denv
neutral
multihit
phenomenon
requir
number
antibodi
bound
viru
exceed
critic
threshold
recent
sever
group
start
dissect
polyclon
monoclon
human
antibodi
respons
denv
human
antibodi
respons
featur
similar
differ
mous
respons
strike
differ
strongli
neutral
mous
antibodi
target
epitop
ediii
wherea
potent
human
antibodi
bind
differ
epitop
viral
envelop
recent
studi
also
indic
prm
antigen
denv
envelop
hitherto
underrecogn
target
human
antibodi
respons
potenti
target
infect
diseas
enhanc
antibodi
field
evolv
rapidli
learn
human
bcell
respons
develop
better
anim
model
dengu
next
year
like
wit
mani
import
discoveri
interact
human
antibodi
denv
lead
better
understand
dengu
pathogenesi
improv
method
evalu
develop
vaccin
manuscript
review
mathew
colleagu
publish
studi
character
human
bcell
respons
follow
primari
secondari
dengu
infect
investig
demonstr
peopl
expos
dengu
bcell
secret
antibodi
bind
e
protein
peptid
deriv
prem
protein
follow
primari
infect
bcell
produc
antibodi
mainli
recogn
e
protein
homolog
serotyp
follow
secondari
infect
e
antibodi
mainli
serotyp
crossreact
antibodi
produc
secondari
infect
display
avid
differ
serotyp
